Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Phase 2 Study of Valproic Acid combinEd With Simvastatin and Gemcitabine/Nab-paclitaxel-based Regimens in Untreated Metastatic Pancreatic Adenocarcinoma Patients (The VESPA Trial).

NCT05821556 is registered in ClinicalTrials.gov with National Cancer Institute, Naples as lead sponsor.

NCT NCT05821556
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05821556 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Phase 2 Study of Valproic Acid combinEd With Simvastatin and Gemcitabine/Nab-paclitaxel-based Regimens in Untreated Metastatic Pancreatic Adenocarcinoma Patients (The VESPA Trial).
Lead sponsor
National Cancer Institute, Naples
Phase
Phase 2
Overall status
Recruiting
Start date
June 12, 2023
Completion date
June 30, 2027
Enrollment
240 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

adenocarcinoma of the pancreas